(Re-)Engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systemic therapy for metastatic disease.
An approach combining redundant controls to restrict the productive infection of adenoviruses to cells that are disrupted in the pRb pathway-a hallmark of human cancer-has resulted in a novel oncolytic virus that may be well suited for systemic administration to treat metastatic disease.
Dubensky
Thomas W
TW
Cancer Research, Cerus Corporation, 2411 Stanwell Dr., Concord, CA 94520, USA. tom_dubensky@ceruscorp.com
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D003673:Defective Viruses; D050684:E2F Transcription Factors; D005818:Genetic Engineering / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D016160:Retinoblastoma Protein / Q000378:metabolism; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism; D014779:Virus Replication
D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D016160:Retinoblastoma Protein; D014157:Transcription Factors